Rationale for Correct Answer

The correct answer is: Selpercatinib

NCCN guideline preferred first-line options for patients with advanced RET fusion-positive NSCLC are selpercatinib or pralsetinib, both of which are FDA approved for this purpose regardless of histology.1,2 Pembrolizumab plus chemotherapy and nivolumab plus ipilimumab are other recommended systemic therapies in the RET-positive setting but are not preferred. Crizotinib is not a recommended option for patients with RET-positive disease.1

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023. Updated April 13, 2023. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450

2. U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications . Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm